Atossa Therapeutics, INC 8-K filings

Atossa Therapeutics announced first quarter 2024 financial results, highlighted by a 100% disease control rate in the EVANGELINE study and a strong cash balance of $84 million.

Atossa Therapeutics announced its year-end 2023 financial results, highlighted by $88.5 million in cash and the full enrollment of two Phase 2 clinical trials, with data expected in the second half of 2024.

Atossa Therapeutics reported its year-end 2023 financial results, highlighted clinical trial progress, and provided a corporate update, including the full enrollment of two Phase 2 studies and the first patient dosed in a new Phase 2 breast cancer prevention study.

Atossa Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Atossa Therapeutics has appointed Dr. Tessa Cigler, a breast cancer specialist, to its Board of Directors to leverage her clinical trial and patient care experience.